Loading...
XHKG1110
Market cap34mUSD
Dec 23, Last price  
0.46HKD
1D
0.00%
1Q
-10.78%
Jan 2017
-63.01%
IPO
-81.80%
Name

Kingworld Medicines Group Ltd

Chart & Performance

D1W1MN
XHKG:1110 chart
P/E
6.65
P/S
0.24
EPS
0.06
Div Yield, %
5.16%
Shrs. gr., 5y
-1.01%
Rev. gr., 5y
0.00%
Revenues
1.08b
+12.63%
556,417,000638,046,000685,562,000705,519,000554,763,000660,323,000713,548,0001,053,527,0001,031,488,0001,078,843,000977,928,000745,383,000847,386,000957,701,0001,078,659,000
Net income
38m
-12.51%
37,244,00042,863,00051,031,00048,535,00047,177,00037,865,00031,205,00046,966,00051,060,00041,005,00043,427,00050,889,00051,211,00043,542,00038,096,000
CFO
42m
-77.33%
158,647,00013,416,000-53,326,00073,203,000-49,849,000-5,230,000102,790,000-2,207,00072,388,00062,385,000132,711,000123,584,00081,199,000186,548,00042,284,000
Dividend
Jun 03, 20240.0338 HKD/sh
Earnings
May 29, 2025

Profile

Kingworld Medicines Group Limited, an investment holding company, distributes branded imported pharmaceutical and healthcare products. The company also supplies pharmaceutical, healthcare, general foodstuffs, and medical products. It offers products for various functional categories, such as cough and phlegm relieving, gastrointestinal, vitamin, orthopedics, cardiovascular, influenza, and other categories under the Nin Jiom Chuan Bei Pei Pa Koa, Taiko Seirogan, Kawai Product Range, Flying Eagle Wood Lok Medicated Oil, Kyushin Pill, and Mentholatum Product Range brands. The company also manufactures and sells electrotherapeutic and physiotherapeutic devices, and general medical examination devices. It serves in the People's Republic of China, Hong Kong, the United States, the United Kingdom, Germany, Italy, Spain, Mexico, and internationally. The company was founded in 1996 and is headquartered in Shenzhen, the People's Republic of China.
URL
https://www.kingworld.com.cn/
IPO date
Nov 25, 2010
Employees
1,019
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,078,659
12.63%
957,701
13.02%
847,386
13.68%
Cost of revenue
1,039,128
900,618
793,352
Unusual Expense (Income)
NOPBT
39,531
57,083
54,034
NOPBT Margin
3.66%
5.96%
6.38%
Operating Taxes
32,292
24,042
18,223
Tax Rate
81.69%
42.12%
33.73%
NOPAT
7,239
33,041
35,811
Net income
38,096
-12.51%
43,542
-14.98%
51,211
0.63%
Dividends
(13,921)
(13,292)
(3,301)
Dividend yield
3.73%
2.51%
0.70%
Proceeds from repurchase of equity
(10,074)
BB yield
1.90%
Debt
Debt current
198,029
279,291
237,506
Long-term debt
168,693
30,776
10,484
Deferred revenue
600
(18,122)
Other long-term liabilities
18,122
Net debt
20,688
(65,910)
(77,978)
Cash flow
Cash from operating activities
42,284
186,548
81,199
CAPEX
(105,535)
(92,913)
(58,319)
Cash from investing activities
(120,634)
(84,049)
(50,835)
Cash from financing activities
4,372
(51,311)
(87,201)
FCF
(103,330)
38,980
(9,128)
Balance
Cash
194,029
256,167
198,405
Long term investments
152,005
119,810
127,563
Excess cash
292,101
328,092
283,599
Stockholders' equity
575,632
549,777
600,776
Invested Capital
761,677
640,086
659,743
ROIC
1.03%
5.08%
5.59%
ROCE
3.69%
5.80%
5.62%
EV
Common stock shares outstanding
591,627
622,500
622,500
Price
0.63
-25.88%
0.85
11.84%
0.76
1.33%
Market cap
372,725
-29.56%
529,125
11.84%
473,100
2.67%
EV
473,731
585,464
531,701
EBITDA
59,606
95,275
88,818
EV/EBITDA
7.95
6.14
5.99
Interest
11,519
12,292
11,782
Interest/NOPBT
29.14%
21.53%
21.80%